BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive: Altogether, these results highlight that mechanism-guided double blockade of BCL-2 and tyrosine kinase may cure CP-CML and potentially also BC-CML patients, making this approach worthy of further clinical testing.